In this article, we will look at the 7 Best Strong Buy European Stocks to Invest In.
European stocks are getting a closer look as investors search beyond the crowded parts of the U.S. market and start paying closer attention to regions where valuation and earnings expectations look more constructive. This is not just about geographic diversification for its own sake. It is also about whether Europe can offer a steadier mix of improving fundamentals, fiscal support, and less demanding multiples at a time when parts of the U.S. market look stretched. J.P. Morgan Asset Management says it is “positive about a broadening of global growth,” a backdrop it believes should “support equity markets outside the US.” Fidelity makes a similar point from a different angle, arguing that “The case for Europe has strengthened considerably.”
The institutional case is fairly direct. J.P. Morgan further contends “European valuations remain attractive,” which matters more now that returns are likely to depend less on multiple expansion and more on actual earnings delivery. Franklin Templeton also argues European equities appear “well positioned for 2026,” supported by “improving earnings momentum” and “supportive valuations.” Fidelity adds that European companies should not be treated as simple macro proxies, describing them instead as global businesses with “resilient balance sheets” and “proven growth profiles.” Put together, these reports are pointing to the same idea that Europe is not just cheaper than the U.S. in headline terms; it may also offer a more interesting hunting ground for selective stock picking.
Against this backdrop, the European stocks still carrying Strong Buy ratings deserve a closer look. That brings us to the 7 Best Strong Buy European Stocks to Invest In.
Our Methodology
We used the Finviz screener to identify European stocks that carry a “Strong Buy” rating from analysts. We then limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
7. ABIVAX Société Anonyme (NASDAQ:ABVX)
On April 2, 2026, ABIVAX Société Anonyme (NASDAQ:ABVX) appointed Michael Nesrallah as chief commercial officer. Michael Nesrallah will lead global commercial strategy and launch preparation for obefazimod as the company moves toward potential regulatory approval, bringing more than 20 years of biopharmaceutical experience, including prior senior leadership roles at Takeda.
On March 24, 2026, Barclays raised the price target on ABIVAX Société Anonyme (NASDAQ:ABVX) to $148 from $142 and maintained an Overweight rating. Barclays said a “clean” Data and Safety Monitoring Board review supports continued ABTECT maintenance, with a readout expected in late Q2.
On March 15, 2026, Jefferies initiated coverage on ABIVAX Société Anonyme (NASDAQ:ABVX) with a Buy rating and a $160 price target. Jefferies described obefazimod as a “differentiated” treatment for ulcerative colitis and said the upcoming Q2 maintenance readout appears “fairly de-risked,” while also pointing to potential in Crohn’s disease.
ABIVAX Société Anonyme (NASDAQ:ABVX) develops therapeutics targeting chronic inflammatory diseases.
6. Aptiv PLC (NYSE:APTV)
On April 6, 2026, Wells Fargo lowered the price target on Aptiv PLC (NYSE:APTV) to $81 from $93 and maintained an Overweight rating. Wells Fargo noted the company completed the spin-off of its Electrical Distribution Systems business into Versigent and said the remaining Aptiv is now focused on higher growth products, with expectations for mid-single-digit growth over market in the next five years, which could support value realization based on updated sum-of-the-parts valuations.
On April 2, 2026, TD Cowen analyst Itay Michaeli lowered the price target on Aptiv PLC (NYSE:APTV) to $93 from $108 and maintained a Buy rating following the spin-off. Itay Michaeli said the valuation is based on 10x 2026E EV/EBITDA and 15x P/E, reflecting adjustments from prior assumptions.
Last month, Aptiv PLC (NYSE:APTV) announced details of the spin-off of its Electrical Distribution Systems business into Versigent, with a record date of March 17, 2026, and distribution before market open on April 1, 2026. Shareholders received one Versigent share for every three Aptiv shares, with cash issued in lieu of fractional shares.
Aptiv PLC (NYSE:APTV) provides hardware and software solutions for automotive and industrial applications.
While we acknowledge the potential of APTV to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than APTV and that has 100x upside potential, check out our report about the cheapest AI stock.
Click to continue reading and see the 5 Best Strong Buy European Stocks to Invest In.
Disclosure: None. Follow Insider Monkey on Google News.
Hedge Fund Resource Center